iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Sold by WoodTrust Financial Corp

WoodTrust Financial Corp cut its holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC) by 2.2% during the fourth quarter, HoldingsChannel reports. The firm owned 11,057 shares of the company’s stock after selling 250 shares during the period. WoodTrust Financial Corp’s holdings in iRhythm Technologies were worth $997,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of iRhythm Technologies in the third quarter valued at approximately $1,497,000. Eagle Asset Management Inc. grew its position in iRhythm Technologies by 44.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 100,655 shares of the company’s stock valued at $7,473,000 after buying an additional 31,193 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in iRhythm Technologies by 38.1% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 707,175 shares of the company’s stock valued at $52,501,000 after buying an additional 195,246 shares during the period. Barclays PLC raised its position in iRhythm Technologies by 34.3% during the 3rd quarter. Barclays PLC now owns 209,247 shares of the company’s stock worth $15,534,000 after buying an additional 53,498 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of iRhythm Technologies by 7.0% in the 3rd quarter. FMR LLC now owns 388,074 shares of the company’s stock worth $28,811,000 after acquiring an additional 25,385 shares during the period.

iRhythm Technologies Stock Down 1.7 %

IRTC stock opened at $107.29 on Wednesday. The company has a debt-to-equity ratio of 9.00, a current ratio of 6.27 and a quick ratio of 6.12. The company’s 50 day simple moving average is $104.80 and its 200-day simple moving average is $85.93. iRhythm Technologies, Inc. has a 12 month low of $55.92 and a 12 month high of $128.52. The firm has a market capitalization of $3.37 billion, a PE ratio of -29.48 and a beta of 1.36.

iRhythm Technologies (NASDAQ:IRTC) last posted its earnings results on Thursday, February 20th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.30. The firm had revenue of $164.33 million for the quarter, compared to analyst estimates of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. Equities analysts expect that iRhythm Technologies, Inc. will post -1.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IRTC has been the topic of a number of recent analyst reports. StockNews.com raised iRhythm Technologies from a “sell” rating to a “hold” rating in a report on Monday, February 24th. Oppenheimer upped their price target on shares of iRhythm Technologies from $105.00 to $120.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. The Goldman Sachs Group raised their price objective on shares of iRhythm Technologies from $91.00 to $124.00 and gave the company a “neutral” rating in a research note on Monday, February 24th. Canaccord Genuity Group boosted their price objective on shares of iRhythm Technologies from $125.00 to $152.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Needham & Company LLC increased their target price on shares of iRhythm Technologies from $125.00 to $138.00 and gave the company a “buy” rating in a report on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.73.

About iRhythm Technologies

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.